Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from President ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

July 7 – With a 90-day negotiating period on country-specific US tariffs is set to expire on July 9, Trump enacts a multitude ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

CVS Health raised its full-year profit forecast after exceeding Wall Street quarterly earnings estimates on Thursday, as ...

Steven Gerrard's daughter Lilly, 21, has shared her first snaps of her baby girl after welcoming newborn with Irish ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Ahead of its release next month, a trailer has arrived online for writer-director Martin Melnick’s psychological horror Lilly ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...